Belfast antibody discovery firm Fusion Antibodies has stated it expects “continued development in monetary efficiency” after reporting a bounce in revenues.
The corporate stated turnover climbed by 14% to £4.8 million for the 12 months to the top of March 2022, with development recorded in all geographical areas.
In a buying and selling replace to the Various Funding Market on the London Inventory Change, Fusion Antibodies stated it had managed to beat the challenges introduced by the Covid-19 pandemic and has discovered growing demand for its providers.
Buyer enquiries are stated to be sturdy and the agency stated it has bolstered its industrial workforce whereas additionally progressing with the seek for a brand new chief government officer following the resignation of Richard Jones in February this 12 months.
Simon Douglas, Chairman of Fusion, stated he was assured for future months.
“We’re happy to have achieved income development in step with expectations in what has been one other difficult 12 months globally because of the pandemic,” he stated. “I’m delighted that the worth of our shopper work is being demonstrated by the successes of our shoppers in reaching growth milestones.
“All our workers members have labored diligently all year long and I wish to thank all of them for his or her helpful contribution. The continuing recruitment of a brand new CEO is progressing as deliberate, and we look ahead to a 12 months with extra alternatives to go to shoppers and attend conferences because the restrictions calm down.
“I’m assured we could have a very good 12 months forward.”
Based in 2001, Fusion Antibodies was spun out of Queens College Belfast and specialises in antibody growth providers for pharmaceutical and different corporations. It launched an preliminary public providing on the AIM market again in 2017.
Whereas the Covid-19 pandemic impacted its operations, it was additionally concerned within the combat towards the virus by leveraging its antigen experience.